Goldman Sachs upgrades Amgen (AMGN) to Neutral from Sell on the heels of the biotech concern's change in management. Analysts with the firm have been calling for a "new strategic direction" for AMGN for quite a while.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs